Intravitreal Aflibercept Injection

DRUG17 trials

Sponsors

Kitano Shigehiko, Shinshu University, Regeneron Pharmaceuticals, Retina Research Institute, LLC, Wills Eye

Conditions

Age Related Macular DegenerationAge-Related Macular DegenerationBranch Retinal Vein Occlusion With Macular EdemaCentral Retinal Vein OcclusionCentral Serous ChorioretinopathyCentral retinal vein occlusion with macular edemaChoroidal NeovascularizationCystoid Macular Edema

Phase 1

Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion

CompletedNCT01724554

Ophthalmic Consultants of BostonCentral Retinal Vein Occlusion, Proliferative Diabetic Retinopathy

Start: 2012-11-30End: 2014-10-31Updated: 2015-05-22

Phase 2

DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact

CompletedNCT00789477

Regeneron PharmaceuticalsDiabetic Macular Edema

Start: 2008-12-31End: 2010-09-30Updated: 2014-09-09

The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy

CompletedNCT01710332

Wills EyeCentral Serous Chorioretinopathy

Start: 2012-10-31End: 2013-06-30Updated: 2017-06-16

Aflibercept Injection for Proliferative Diabetic Retinopathy

CompletedNCT01805297

University of OklahomaVitreous Hemorrhage

Start: 2013-03-31End: 2015-11-30Updated: 2023-12-27

Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy

CompletedNCT01971190

Asan Medical CenterCentral Serous Chorioretinopathy

Start: 2013-10-31End: 2015-05-31Updated: 2015-06-25

IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD

CompletedNCT02462889

Jeffrey S HeierAge-Related Macular Degeneration

Start: 2015-06-30End: 2019-03-31Updated: 2025-11-14

The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy

CompletedNCT03006081

Asan Medical CenterDiabetic Retinopathy

Start: 2016-04-14End: 2018-08-30Updated: 2025-12-02

Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair

M. Ali Khan, MDProliferative Vitreoretinopathy, Retinal Detachment With Multiple Breaks, Unspecified Eye

Start: 2020-10-15End: 2023-12-15Target: 150Updated: 2022-05-03

Phase 4

Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results

Retina Research Institute, LLCAge Related Macular Degeneration

Start: 2012-10-31End: 2017-12-31Updated: 2017-10-27

Variable Interval Versus Set Interval Aflibercept for DME

CompletedNCT02392364

California Retina ConsultantsCystoid Macular Edema, Diabetic Macular Edema

Start: 2015-04-15End: 2018-11-15Updated: 2019-01-03

EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection

CompletedNCT02689518

University of California, San DiegoMacular Degeneration, Wet Macular Degeneration

Start: 2014-04-30End: 2019-11-12Updated: 2021-03-25

Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion

Yeungnam University College of MedicineBranch Retinal Vein Occlusion With Macular Edema

Start: 2018-01-25End: 2020-09-30Target: 49Updated: 2019-01-09

Unknown Phase

Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration

CompletedNCT01773954

MidAtlantic RetinaAge-Related Macular Degeneration, Macular Degeneration

Start: 2013-02-28End: 2016-03-31Updated: 2018-05-02

Study of Treat and Extend Regimen using Aflbercept for macular edema (CRVO-ME) associated with central retinal vein occlusion

RecruitingJPRN-UMIN000031718

Shinshu UniversityCentral retinal vein occlusion with macular edema

Start: 2018-03-14Target: 40Updated: 2026-06-29

The effect of an anti-VEGF drug on proliferative retinopathy.

Active, not recruitingJPRN-jRCTs031180307

Kitano ShigehikoDiabetic retinopathy

Start: 2018-08-24Target: 30Updated: 2026-06-29

Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV

CompletedNCT05662943

Kim's Eye HospitalAge-Related Macular Degeneration, Choroidal Neovascularization, Polypoidal Choroidal Vasculopathy

Start: 2022-12-05End: 2023-11-30Updated: 2023-12-14

Change in Ocular Perfusion After Intravitreal Anti-VEGF in Patients with Age-related Maculopathy or Diabetic Macula Edema

CompletedNCT06878573

Augenabteilung Allgemeines Krankenhaus LinzAge Related Macular Degeneration, Diabetic Macular Edema

Start: 2023-11-22End: 2024-07-30Updated: 2025-03-17

Related Papers

Impact of Prolonged Persisting Subretinal Fluid on the Outcome of Aflibercept Treatment in Neovascular Age-Related Macular Degeneration

Journal of Ocular Pharmacology and Therapeutics2024-03-013 citations

Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against Conversion to Exudative Age-Related Macular Degeneration in High-risk Eyes

JAMA Ophthalmology2021-03-1833 citations

Efficacy of intravitreal AFlibercept injection For Improvement of retinal Nonperfusion In diabeTic retinopathY (AFFINITY study)

BMJ Open Diabetes Research & Care2020-10-0114 citations

Intravitreal Aflibercept for the Treatment of Subacute Central Serous Chorioretinopathy

Journal of VitreoRetinal Diseases2017-03-018 citations

A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study

British Journal of Ophthalmology2015-01-1667 citations